For the Inventor, By the Inventor

Enter inventor name

Doylestown, PA, United States of America

Walter R Strapps

USPTO Granted Patents = 19 (Patent Applications = 13)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 51(Granted Patents)

Location History:

San Mateo, CA (US) (2013)
Doylestown, PA (US) (2013 - 2024)
Dedham, MA (US) (2018 - 2024)

Company Filing History:

Sirna Therapeutics, Inc.

Intellia Therapeutics, Inc.

Merck Sharp + Dohme Corp.

Sima Therapeutics, Inc.

5. 1 out of 832,891

Other

patents

Years Active: 2013-2025

Loading Chart...

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12460205 - Compositions and methods for treating alpha-1 antitrypsin deficiency (2025-11-04),

2. 12173284 - Modified guide RNAs (2024-12-24),

3. 11965165 - Compositions and methods for TTR gene editing and treating ATTR amyloidosis (2024-04-23),

4. 11952573 - RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) (2024-04-09),

5. 11795460 - Compositions and methods for TTR gene editing and treating ATTR amyloidosis (2023-10-24),

6. 11549107 - Compositions and methods for treating alpha-1 antitrypsin deficiency (2023-01-10),

7. 11529428 - Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety (2022-12-20),

8. 11479767 - Modified guide RNAs (2022-10-25),

9. 11332745 - RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA) (2022-05-17),

10. 10729787 - Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety (2020-08-04),

11. 10577606 - RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) (2020-03-03),

12. 10246714 - RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) (2019-04-02),

13. 10004814 - Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety (2018-06-26),

14. 9850491 - RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) (2017-12-26),

15. 9447420 - RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (SINA) (2016-09-20),

Title: The Innovative Journey of Walter R. Strapps

Introduction: Walter R. Strapps, a distinguished inventor hailing from Doylestown, PA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Walter R. Strapps holds several patents in various technological domains, including advancements in renewable energy systems, artificial intelligence algorithms, and medical devices.

Career Highlights: With a career spanning over two decades, Walter R. Strapps has been at the forefront of innovation, leading research teams and spearheading projects that have revolutionized industries.

Collaborations: Throughout his career, Walter R. Strapps has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life, showcasing his ability to work across disciplines and sectors.

Conclusion: Walter R. Strapps' relentless pursuit of innovation and his passion for pushing the boundaries of technology have solidified his position as a visionary inventor, inspiring the next generation of innovators to dream big and create a better future.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…